MedTrace Logo

Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors

NCT00116857 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2012-09-12

Study results available
· View outcomes & findings →

Summary

This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).

Conditions

Interventions

DRUG

Sertraline/omega-3

Sertraline (50 mgs) plus omega-3 (2 grams)

DRUG

Sertraline/Corn Oil

Sertraline (50 mgs) plus corn oil (2 grams) (placebo)

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Robert M. Carney, PhD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2009-06-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116857 on ClinicalTrials.gov